BJL
CORT icon

Brighton Jones LLC’s Corcept Therapeutics CORT Stock Holding History

Brighton Jones LLC’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$649K Buy
+7,463
New +$451K 0.01% 687
2025
Q4 		– Sell
-3,483
Closed -$289K – 226
2025
Q3 		$289K Buy
+3,483
New +$252K 0.01% 826

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brighton Jones LLC's CORT Position: Q2 2026 in Review

Brighton Jones LLC opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 7,463 shares worth $649K. The stake represents 0.01% of the portfolio and ranks #687 among its holdings. This is a return to the name: Brighton Jones LLC previously reported a position in CORT as recently as Q3 2025.

Brighton Jones LLC first reported a position in CORT in Q3 2025 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Brighton Jones LLC held 7,463 shares of Corcept Therapeutics worth $649K as of Q2 2026.
  • Corcept Therapeutics was a new Brighton Jones LLC position in Q2 2026.
  • Corcept Therapeutics made up 0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #687 holding.
  • Brighton Jones LLC first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.